KR100822655B1 - 5-하이드록시트립타민-6 리간드로서의 1-아릴설포닐- 또는 1-알킬설포닐-헤테로사이클릴벤즈아졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물 - Google Patents
5-하이드록시트립타민-6 리간드로서의 1-아릴설포닐- 또는 1-알킬설포닐-헤테로사이클릴벤즈아졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR100822655B1 KR100822655B1 KR1020037006000A KR20037006000A KR100822655B1 KR 100822655 B1 KR100822655 B1 KR 100822655B1 KR 1020037006000 A KR1020037006000 A KR 1020037006000A KR 20037006000 A KR20037006000 A KR 20037006000A KR 100822655 B1 KR100822655 B1 KR 100822655B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- substituted
- halogen
- unsubstituted
- piperazin
- Prior art date
Links
- 0 C(C*CC1)CN1c1c2nc[n]c2ccc1 Chemical compound C(C*CC1)CN1c1c2nc[n]c2ccc1 0.000 description 2
- MUQFMGBYYAOIJK-UHFFFAOYSA-N Brc1cccc2c1nc[nH]2 Chemical compound Brc1cccc2c1nc[nH]2 MUQFMGBYYAOIJK-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N C1CNCCNC1 Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24511800P | 2000-11-02 | 2000-11-02 | |
| US60/245,118 | 2000-11-02 | ||
| PCT/US2001/045389 WO2002036562A2 (fr) | 2000-11-02 | 2001-10-31 | 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030040566A KR20030040566A (ko) | 2003-05-22 |
| KR100822655B1 true KR100822655B1 (ko) | 2008-04-17 |
Family
ID=22925357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020037006000A KR100822655B1 (ko) | 2000-11-02 | 2001-10-31 | 5-하이드록시트립타민-6 리간드로서의 1-아릴설포닐- 또는 1-알킬설포닐-헤테로사이클릴벤즈아졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20020115670A1 (fr) |
| EP (2) | EP1343756A2 (fr) |
| JP (1) | JP4184077B2 (fr) |
| KR (1) | KR100822655B1 (fr) |
| CN (1) | CN1222511C (fr) |
| AR (1) | AR034270A1 (fr) |
| AU (2) | AU2002220051B2 (fr) |
| BR (1) | BR0115102B1 (fr) |
| CA (1) | CA2426031C (fr) |
| EA (1) | EA006205B1 (fr) |
| HU (1) | HUP0303756A3 (fr) |
| IL (2) | IL155443A0 (fr) |
| MX (1) | MXPA03003800A (fr) |
| NO (1) | NO326610B1 (fr) |
| NZ (1) | NZ525592A (fr) |
| PL (1) | PL213134B1 (fr) |
| TW (1) | TWI282787B (fr) |
| WO (1) | WO2002036562A2 (fr) |
| ZA (1) | ZA200304188B (fr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL361887A1 (en) | 2000-10-20 | 2004-10-04 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
| KR100600240B1 (ko) * | 2001-06-07 | 2006-07-13 | 에프. 호프만-라 로슈 아게 | 5-ｈｔ6 수용체 친화도를 갖는 신규한 인돌 유도체 |
| JP2005501019A (ja) * | 2001-06-15 | 2005-01-13 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６レセプター親和性を有する４−ピペラジニルインドール誘導体 |
| CN1321110C (zh) * | 2001-06-15 | 2007-06-13 | 弗·哈夫曼-拉罗切有限公司 | 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物 |
| EP1408976B3 (fr) * | 2001-07-20 | 2010-08-25 | Psychogenics Inc. | Traitement des troubles de deficit de l'attention/hyperactivite |
| GB0203811D0 (en) | 2002-02-18 | 2002-04-03 | Glaxo Group Ltd | Compounds |
| PT1497266E (pt) | 2002-03-27 | 2008-09-10 | Glaxo Group Ltd | Derivados de quinolina e sua utilização como ligandos 5-ht6 |
| KR100657056B1 (ko) | 2002-06-05 | 2006-12-13 | 에프. 호프만-라 로슈 아게 | 중추 신경계 장애의 치료를 위한 5-ｈｔ6-수용체조절제로서 1-설폰일-4-아미노알콕시 인돌 유도체 |
| DE60322551D1 (de) | 2002-09-17 | 2008-09-11 | Hoffmann La Roche | 2,4-substituierte indole und deren verwendung als 5-ht6 modulatoren |
| PL378120A1 (pl) * | 2003-02-14 | 2006-03-06 | Wyeth | Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy |
| MXPA06000795A (es) | 2003-07-22 | 2006-08-23 | Arena Pharm Inc | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo. |
| SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
| NZ546887A (en) | 2003-11-03 | 2009-04-30 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| BRPI0513713A (pt) | 2004-07-28 | 2008-05-13 | Glaxo Group Ltd | derivados de piperazina úteis para o tratamento de distúrbios gastrointestinais |
| CA2619010C (fr) * | 2005-08-15 | 2013-10-01 | Wyeth | Derives de 3-sulfonylindazole substitues en tant que ligands de 5-hydroxytryptamine-6 |
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| WO2007098418A1 (fr) * | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Composes ayant une affinite pour le recepteur 5-ht6 |
| TW200808709A (en) | 2006-03-31 | 2008-02-16 | Glaxo Group Ltd | Novel compounds |
| EP2001865A1 (fr) * | 2006-04-05 | 2008-12-17 | Wyeth a Corporation of the State of Delaware | Dérivés de sulfonyl-3-hétérocyclylindazole utilisés en tant que ligands de la 5-hydroxytryptamine-6 |
| WO2007120596A1 (fr) * | 2006-04-12 | 2007-10-25 | Wyeth | DÉRIVÉS DE DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6 |
| DK2121602T3 (en) * | 2007-01-08 | 2015-04-07 | Suven Life Sciences Ltd | 4- (Heterocyclyl) alkyl-N- (arylsulfonyl) -INDOLFORBINDELSER and their use as 5-HT 6 ligands |
| PL2114878T3 (pl) * | 2007-01-08 | 2011-05-31 | Suven Life Sciences Ltd | Związki 5-(heterocyklilo)alkilo-N-(arylosulfonylo)indolowe i ich zastosowanie jako ligandy 5-HT6 |
| AU2008216032A1 (en) * | 2007-02-16 | 2008-08-21 | Memory Pharmaceuticals Corporation | 6 ' substituted indole and indazole derivatives having 5-HT6 receptor affinity |
| TW200848021A (en) | 2007-03-06 | 2008-12-16 | Wyeth Corp | Sulfonylated heterocycles useful for modulation of the progesterone receptor |
| ATE513810T1 (de) | 2007-05-03 | 2011-07-15 | Suven Life Sciences Ltd | Aminoalkoxy-aryl-sulfonamidverbindungen und ihre verwendung als 5-ht6-liganden |
| AU2008286760A1 (en) * | 2007-08-15 | 2009-02-19 | Memory Pharmaceuticals Corporation | 3' substituted compounds having 5-HT6 receptor affinity |
| EP2508177A1 (fr) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| WO2009123714A2 (fr) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb> |
| US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
| US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| WO2010032257A1 (fr) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Composés arylindolylsulfonamides et leur utilisation en tant que ligands de 5-ht<sb>6</sb> |
| ES2424036T3 (es) | 2008-09-17 | 2013-09-26 | Suven Life Sciences Limited | Compuestos de amina de arilsulfonamida y su uso como ligandos de 5-HT6 |
| WO2010062321A1 (fr) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées |
| UA100192C2 (en) * | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
| EP2424844A1 (fr) * | 2009-04-30 | 2012-03-07 | Abbott GmbH & Co. KG | Composés de benzènesulfonanilide pour le traitement de troubles répondant à la modulation du récepteur 5-ht6 de la sérotonine |
| US8940716B2 (en) | 2010-05-06 | 2015-01-27 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as GPR119 modulators |
| CA2799154A1 (fr) | 2010-05-12 | 2011-11-17 | Abbvie Inc. | Inhibiteurs indazoliques des kinases |
| PL395469A1 (pl) | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego |
| IN2013MU02611A (fr) | 2013-08-07 | 2015-06-12 | Cadila Healthcare Ltd | |
| WO2015090233A1 (fr) | 2013-12-20 | 2015-06-25 | Sunshine Lake Pharma Co., Ltd. | Composés hétérocycliques aromatiques et leur utilisation dans les produits pharmaceutiques |
| CN103880750A (zh) * | 2014-03-18 | 2014-06-25 | 上海皓元生物医药科技有限公司 | 一种替格列汀关键中间体的制备方法 |
| CN105541693B (zh) * | 2014-07-08 | 2018-10-16 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
| US9550754B2 (en) * | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN107108556B (zh) * | 2014-11-03 | 2020-09-29 | 艾欧米制药有限公司 | 药用化合物 |
| EP4119141A1 (fr) | 2015-06-12 | 2023-01-18 | Axovant Sciences GmbH | Nelotanserin pour la prophylaxie et le traitement d'un trouble du comportement en sommeil paradoxal |
| CA2992518A1 (fr) | 2015-07-15 | 2017-01-19 | Axovant Sciences Gmbh | Derives d'arylheretoaryl uree en tant que modulateurs du recepteur serotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associees a une maladie neurodegenerative |
| JP7007374B2 (ja) * | 2016-09-23 | 2022-01-24 | ノバルティス アーゲー | 腱及び／又は靭帯損傷に使用するためのインダゾール化合物 |
| TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996003400A1 (fr) * | 1994-07-26 | 1996-02-08 | Pfizer Inc. | Derives 4-indole utilises comme agonistes et antagonistes de la serotonine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849759A (en) * | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
| GB9716656D0 (en) * | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| DK0930302T3 (da) * | 1998-01-16 | 2003-07-21 | Hoffmann La Roche | Benzosulfonderivater |
| US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| SE0002754D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
| PL361887A1 (en) * | 2000-10-20 | 2004-10-04 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
-
2001
- 2001-10-31 HU HU0303756A patent/HUP0303756A3/hu unknown
- 2001-10-31 EP EP01992697A patent/EP1343756A2/fr not_active Withdrawn
- 2001-10-31 NZ NZ525592A patent/NZ525592A/en not_active IP Right Cessation
- 2001-10-31 JP JP2002539322A patent/JP4184077B2/ja not_active Expired - Fee Related
- 2001-10-31 CN CNB018216587A patent/CN1222511C/zh not_active Expired - Fee Related
- 2001-10-31 IL IL15544301A patent/IL155443A0/xx unknown
- 2001-10-31 EP EP10177536A patent/EP2298738B1/fr not_active Expired - Lifetime
- 2001-10-31 PL PL362138A patent/PL213134B1/pl unknown
- 2001-10-31 BR BRPI0115102-9B1A patent/BR0115102B1/pt not_active IP Right Cessation
- 2001-10-31 EA EA200300528A patent/EA006205B1/ru not_active IP Right Cessation
- 2001-10-31 AU AU2002220051A patent/AU2002220051B2/en not_active Ceased
- 2001-10-31 MX MXPA03003800A patent/MXPA03003800A/es active IP Right Grant
- 2001-10-31 KR KR1020037006000A patent/KR100822655B1/ko not_active IP Right Cessation
- 2001-10-31 WO PCT/US2001/045389 patent/WO2002036562A2/fr active IP Right Grant
- 2001-10-31 CA CA2426031A patent/CA2426031C/fr not_active Expired - Fee Related
- 2001-10-31 AU AU2005102A patent/AU2005102A/xx active Pending
- 2001-11-01 TW TW1-ARYL-ORA patent/TWI282787B/zh not_active IP Right Cessation
- 2001-11-01 AR ARP010105112A patent/AR034270A1/es unknown
- 2001-11-01 US US10/003,015 patent/US20020115670A1/en not_active Abandoned
-
2003
- 2003-04-15 IL IL155443A patent/IL155443A/en not_active IP Right Cessation
- 2003-04-30 NO NO20031977A patent/NO326610B1/no not_active IP Right Cessation
- 2003-05-29 ZA ZA200304188A patent/ZA200304188B/en unknown
- 2003-12-04 US US10/728,330 patent/US20040132741A1/en not_active Abandoned
- 2003-12-04 US US10/727,956 patent/US20040087595A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996003400A1 (fr) * | 1994-07-26 | 1996-02-08 | Pfizer Inc. | Derives 4-indole utilises comme agonistes et antagonistes de la serotonine |
Non-Patent Citations (1)
| Title |
|---|
| Bioorg. Med. Chem. Lett. 10, pp.1719-1721, 2000 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100822655B1 (ko) | 5-하이드록시트립타민-6 리간드로서의 1-아릴설포닐- 또는 1-알킬설포닐-헤테로사이클릴벤즈아졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| US7541370B2 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | |
| AU2002251811B2 (en) | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| JP4323810B2 (ja) | ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロシクリルオキシ−、−チオキシ−および−アミノベンザゾール誘導体 | |
| AU2002220051A1 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | |
| KR100985140B1 (ko) | 5-하이드록시트립타민-6 리간드로서의 인돌릴알킬아민 유도체 | |
| US6831094B2 (en) | Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| US20090239863A1 (en) | 1-aryl-or 1- alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20120329 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20130329 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20160330 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20170330 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20180329 Year of fee payment: 11 |
|
| LAPS | Lapse due to unpaid annual fee |